Search company, investor...

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$8.4M

Valuation

$0000 

About Fiagon

Fiagon operates as an electromagnetic-based surgical navigation company. The company develops navigation of instruments for spine, neuro, and ear-nose-throat (ENT) surgery. It specializes in navigation for surgery, medical technology, spine navigation, brain navigation, and ENT navigation. It was founded in 2007 and is based in Brandenburg, Germany. In September 2020, Fiagon was acquired by Intersect ENT.

Headquarters Location

Neuendorfstrabe 23b

Hennigsdorf, 16761,

Germany

+49 3302 201 21 10

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing Fiagon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fiagon is included in 1 Expert Collection, including Digital Health.

D

Digital Health

10,565 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Fiagon Patents

Fiagon has filed 15 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Surgical instruments
  • Celestial coordinate system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/13/2021

8/22/2023

Surgical instruments, Electromagnetism, Medical equipment, Neurosurgery, Quantum mechanics

Grant

Application Date

7/13/2021

Grant Date

8/22/2023

Title

Related Topics

Surgical instruments, Electromagnetism, Medical equipment, Neurosurgery, Quantum mechanics

Status

Grant

Latest Fiagon News

With the FTC’s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT

May 13, 2022

MedCity News With the FTC’s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC's concerns. Shares0 It has in some ways been a long time coming, but Medtronic ‘s $1.1 billion acquisition of medtech company Intersect ENT is now complete, the Dublin-based device maker announced Friday . Earlier this week, the FTC announced that Medtronic would have to divest an Intersect subsidiary —selling surgical navigation company Fiagon to the biotech firm Homeostatis—to get approval for the acquisition. Intersect, which is based in Menlo Park, California, is focused on advancing ear, nose and throat treatment. But the FTC expressed concerns that Medtronic’s acquisition of the company could lead to higher prices and reduced innovation; and it required Medtronic to offload Fiagon no later than 10 days after it acquired Intersect. “Additionally, Medtronic and Intersect must obtain prior approval from the FTC for 10 years before buying ENT navigation systems and balloon sinus dilation assets to address any future attempts to consolidate these important markets,” the FTC ordered. After agreeing to the agency’s terms, Medtronic got the OK to move ahead, following more than a decade of buildup to the deal. Medtronic first invested in Intersect in 2010. It has had a close relationship with Intersect since, and investors had long speculated Medtronic might buy the company. Finally, last August, Medtronic announced it was moving forward with the acquisition, which it completed Friday. One thing that made Intersect a particularly attractive target to the device maker is its steroid-coated stents, according to Medtronic. The sinus implants are used to treat chronic rhinosinusitis, a common chronic condition where spaces inside the nose and sinuses become inflamed, causing symptoms ranging from a lingering cold to headache. Intersect’s Propel sinus implants are used in conjunction with sinus surgery, while its Sinuva implants are a nonsurgical treatment for nasal polyps, noncancerous growths lining the nose and sinuses. Intersect was the first company to get FDA clearance for these types of devices. Medtronic said the acquisition will broaden its device offerings and improve care for patients with conditions like chronic sinusitis, or CRS. “By combining Intersect ENT’s groundbreaking localized drug delivery products with the leading navigation and powered instruments of Medtronic, we can now equip physicians with the right tools for many unique patient needs,” said Vince Racano, president of Medtronic’s ENT business, in a statement. “This acquisition expands our portfolio, and we can now provide a more comprehensive continuum of care for CRS patients while supporting the bold ambition of Medtronic to be the global healthcare technology leader.” After the completion of the acquisition was announced, the device maker saw its stock price rise by more than $1.60 to over $102 per share in trading Friday morning on the New York Stock Exchange. Photo: maxsattana, Getty Images Promoted

Fiagon Frequently Asked Questions (FAQ)

  • When was Fiagon founded?

    Fiagon was founded in 2007.

  • Where is Fiagon's headquarters?

    Fiagon's headquarters is located at Neuendorfstrabe 23b, Hennigsdorf.

  • What is Fiagon's latest funding round?

    Fiagon's latest funding round is Acquired.

  • How much did Fiagon raise?

    Fiagon raised a total of $8.4M.

  • Who are the investors of Fiagon?

    Investors of Fiagon include Intersect ENT, German Startups Group, Donghai Securities and High-Tech Grunderfonds.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.